A study of the effect of conversion to Myfortic on quality of life in patients with gastrointestinal (GI) symptoms related to MMF therapy after renal transplantation (MYQOL)

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-005071-42

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to assess whether treatment with an enteric coated formulation of mycophenolic acid (MPA) permits higher MPA doses to be maintained, than treatment with standard MMF therapy, in patients with demonstrated susceptibility to gastro intestinal side effects


Critère d'inclusion

  • renal transplantation